Pfizer Korea decides to lower insurance price of Norvasc by 1 won

Pfizer Korea said the government should cut down the reimbursement price of Norvasc (amlopidpine), a long-acting calcium channel blocker, by 1 won from this April.

The company said, "The government has informed us of its proposed reduction on Norvasc based on a new actually transacted minimum price system and our opposition against this notice was unfortunately disregarded by the government...